Last reviewed · How we verify
Empa
Empagliflozin is an SGLT2 inhibitor that blocks glucose reabsorption in the kidney, promoting urinary glucose excretion and lowering blood glucose levels.
Empagliflozin is an SGLT2 inhibitor that blocks glucose reabsorption in the kidney, promoting urinary glucose excretion and lowering blood glucose levels. Used for Type 2 diabetes mellitus, Heart failure with reduced ejection fraction, Chronic kidney disease.
At a glance
| Generic name | Empa |
|---|---|
| Sponsor | Beni-Suef University |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 (sodium-glucose cotransporter 2) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Empagliflozin selectively inhibits sodium-glucose cotransporter 2 (SGLT2) in the proximal tubule of the nephron. By blocking SGLT2, the drug prevents reabsorption of filtered glucose, leading to increased urinary glucose excretion (glycosuria) and reduced blood glucose concentrations. This mechanism is independent of insulin secretion or action, making it effective across a range of glycemic states.
Approved indications
- Type 2 diabetes mellitus
- Heart failure with reduced ejection fraction
- Chronic kidney disease
Common side effects
- Genital mycotic infections
- Urinary tract infections
- Polyuria
- Hypotension
- Diabetic ketoacidosis
Key clinical trials
- A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) (PHASE3)
- Empagliflozin Adjunctive Therapy in Bipolar Depression (NA)
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (PHASE1, PHASE2)
- A Study Between Dapagliflozin and Empagliflozin Effect on NAFLD in Patients With Type 2 Diabetes. (PHASE4)
- Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml/Min/1.73m2 (PHASE4)
- Effect of Empagliflozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegravir-Based Therapy (PHASE2)
- Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD) (PHASE4)
- SNIFF - Combo INI+EMPA Trial (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Empa CI brief — competitive landscape report
- Empa updates RSS · CI watch RSS
- Beni-Suef University portfolio CI